Disorders of Immunity and Respiration of the Pediatric Critical Patients Research Group, Institut Recerca Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
Pediatric Intensive Care Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
PLoS One. 2021 Oct 22;16(10):e0254757. doi: 10.1371/journal.pone.0254757. eCollection 2021.
Procalcitonin is a useful biomarker for predicting bacterial infection after cardiac surgery. However, sometimes procalcitonin rises following cardiac surgery without a confirmation of bacterial infection. The aim was to analyse procalcitonin levels in children without a bacterial infection after cardiac surgery.
This is a prospective, observational study of children <18 years old admitted to the pediatric intensive care unit after cardiac surgery.
1,042 children were included, 996 (95.6%) without a bacterial infection. From them, severe complications occurred in 132 patients (13.3%). Procalcitonin increased differentially depending on the type of complication. Patients who presented a poor outcome (n = 26, 2.6%) had higher procalcitonin values in the postoperative period than the rest of patients (<24 hours: 5.8 ng/mL vs. 0.6 ng/mL; 24-48 hours, 5.1 ng/mL vs. 0.8 ng/mL, and 48-72 hours, 5.3 ng/mL vs. 1.2 ng/mL), but these values remained stable over time (p = 0.732; p = 0.110). The AUC for procalcitonin for predicting poor outcome was 0.876 in the first 24 hours. The cut-off point to predict poor outcome was 2 ng/mL in the first 24 hours (sensitivity 86.9%, specificity 77.3%). Patients with bacterial infection (n = 46) presented higher values of procalcitonin initially, but they decreased in the 48-72 hours period (<24 hours: 4.9 ng/mL; 24-48 hours, 5.8 ng/mL, and 48-72 hours, 4.5 ng/mL).
A procalcitonin value<2 ng/mL may indicate the absence of infection and poor outcome after cardiac surgery. The evolution of the values of this biomarker might help to discern between infection (where procalcitonin will decrease) and poor outcome (where procalcitonin will not decrease).
降钙素原是预测心脏手术后细菌感染的有用生物标志物。然而,有时心脏手术后降钙素原升高,但没有细菌感染的确认。目的是分析心脏手术后无细菌感染的儿童降钙素原水平。
这是一项对心脏手术后入住儿科重症监护病房的<18 岁儿童进行的前瞻性、观察性研究。
共纳入 1042 名儿童,其中 996 名(95.6%)无细菌感染。其中 132 名(13.3%)患者发生严重并发症。降钙素原的升高因并发症类型而异。预后不良的患者(n=26,2.6%)在术后期间的降钙素原值高于其他患者(<24 小时:5.8ng/mL 比 0.6ng/mL;24-48 小时:5.1ng/mL 比 0.8ng/mL,48-72 小时:5.3ng/mL 比 1.2ng/mL),但这些值随时间保持稳定(p=0.732;p=0.110)。24 小时内降钙素原预测不良预后的 AUC 为 0.876。24 小时内预测不良预后的降钙素原截断值为 2ng/mL(敏感性 86.9%,特异性 77.3%)。细菌感染患者(n=46)最初的降钙素原值较高,但在 48-72 小时期间下降(<24 小时:4.9ng/mL;24-48 小时:5.8ng/mL,48-72 小时:4.5ng/mL)。
心脏手术后降钙素原<2ng/mL 可能提示无感染和不良预后。该生物标志物的变化可能有助于区分感染(降钙素原降低)和不良预后(降钙素原不降低)。